



TSDiffusion-weighted magnetic resonance imaging can
be used in place of positron emission tomography for
N staging of non–small cell lung cancer with fewer
false-positive results
Hiroaki Nomori, MD, PhD,a Takeshi Mori, MD, PhD,a Koei Ikeda, MD, PhD,a Koichi Kawanaka, MD, PhD,b
Shinya Shiraishi, MD, PhD,b Kazuhiro Katahira, MD, PhD,c and Yasuyuki Yamashita, MD, PhDbObjective: One of the deficiencies of positron emission tomography for N staging
in lung cancer is a false-positive result caused by concurrent lymphadenitis. Re-
cently, diffusion-weighted magnetic resonance imaging has been reported to be
able to image tumors of body organs. The aim of this study is to examine the use-
fulness of diffusion-weighted magnetic resonance imaging for N staging of non–
small cell lung cancer compared with positron emission tomography–computed to-
mography.
Methods: Both positron emission tomography–computed tomography and diffusion-
weighted magnetic resonance imaging were prospectively used in 88 patients before
surgical intervention for non–small cell lung cancer to examine 734 lymph node sta-
tions. The diagnostic results of positron emission tomography–computed tomography
and diffusion-weighted magnetic resonance imaging were compared. The diameters
of the metastatic foci within lymph nodes were measured on hematoxylin and
eosin–stained sections to compare the detectable size of metastatic foci between pos-
itron emission tomography–computed tomography and diffusion-weighted magnetic
resonance imaging.
Results: The accuracy of N staging in the 88 patients was 0.89 with diffusion-
weighted magnetic resonance imaging, which was significantly higher than the value
of 0.78 obtained with positron emission tomography–computed tomography (P 5
.012), because of less overstaging in the former. Among the 734 lymph node stations
examined pathologically, 36 hadmetastases, and the other 698 did not. Although there
was no significant difference in the diagnosis of the 36 metastatic lymph node stations
between the 2 methods, diffusion-weighted magnetic resonance imaging was more
accurate for diagnosing the 698 nonmetastatic stations than positron emission tomog-
raphy–computed tomography because of fewer false-positive results (P5 .002). The
detectable size of metastatic foci within lymph nodes was 4 mm in both positron emis-
sion tomography–computed tomography and diffusion-weighted magnetic resonance
imaging.
Conclusions:Diffusion-weighted magnetic resonance imaging can be used in place of
positron emission tomography–computed tomography for N staging of non–small cell
lung cancer with fewer false-positive results compared with positron emission tomog-
raphy–computed tomography.
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everal noninvasive diagnostic procedures are used for
preoperative N staging in patients with non–small cell
lung cancer (NSCLC), including computed
tomography (CT), magnetic resonance imaging (MRI), and
positron emission tomography (PET). However, CT is not
sufficiently sensitive or specific for diagnosing lymph node
metastases because a size of 1 cm or larger is the only crite-
rion used to differentiate benign from malignant lymph no-
des. In recent years fluorodeoxyglucose (FDG)–PET has
been reported to be able to detect metastatic lymph nodes
smaller than 1 cm.1-4 Several meta-analytic studies have
demonstrated PET to be superior to CT for N staging in
lung cancer.5-7 However, one of the deficiencies of PET for
N staging is a false-positive result for concurrent lymphade-
nitis associated with NSCLC.1,8
Recent advances in MRI gradient technology allow ac-
quisition of diffusion-weighted magnetic resonance imaging
(DWI), which provides excellent tissue contrast based on
difference in the diffusion of water molecules among tissues
and is different from ordinary T1- and T2-weighted images.
Because the diffusion of water molecules is restricted by in-
tracellular organelles and macromolecules, any architectural
changes in the proportion of extracellular to intracellular
water protons will alter the signal intensity of DWI and
the apparent diffusion coefficient (ADC).9-11 Malignant tu-
mors have increased cellularity, larger nuclei with more
abundant macromolecular proteins, larger nuclear cytoplas-
mic ratios, and less extracellular space compared with
values in normal tissue. Therefore diffusion of water mole-
cules in malignant tumors is usually restricted compared
with that in normal tissue, resulting in a decreased ADC
value.12,13
Although the clinical utility of DWI was initially estab-
lished in the central neural system, application of this tech-
nique to body organs has been considered difficult because
DWI is highly sensitive to motion artifacts caused not only
by breathing but also by the beats of the heart and aorta.14
However, the recent development of fast imaging tech-
niques, such as echoplanar imaging and parallel imaging,
has improved DWI for use in body organs.15,16 In addition
to these methods, 3-dimensional display of DWI with a re-
versed gray scale can also produce images similar to PET
images.12 The further recent development in fusion software,
which overlays DWI onto ordinary magnetic resonance
images, can identify the anatomic location of regions with
intense signals on DWI. DWI has been recently reported
to be able to show body tumors, including colorectal cancer,
prostate cancer, and breast cancer.13,17,18 Our recent study
has also shown that DWI is useful for differentiating be-
tween malignant and benign pulmonary nodules as well as
PET-CT (data not shown). However, there have been no re-
ports for N staging of malignancies. In this study we evalu-
ated N staging of NSCLC by using DWI compared with
PET-CT.The Journal of ThoAbbreviations and Acronyms
ADC 5 apparent diffusion coefficient
CR 5 contrast ratio






MRI 5 magnetic resonance imaging
NSCLC 5 non–small cell lung cancer
PET 5 positron emission tomography
STIR 5 short tau inversion recovery
SUV 5 standard uptake value
TE 5 echocardiographic time
TN 5 true-negative
TP 5 true-positive
TR 5 repetition time
Materials and Methods
Eligibility
The study protocol for examining FDG-PET and DWI in patients
with suspected NSCLC before undergoing surgical intervention
was approved by the Ethics Committee of Kumamoto University
Hospital in January 2006. Informed consent was obtained from all
patients after discussing the risks and benefits of the study with their
surgeons.
Patients
Between February 2006 andMay 2007, 93 patients with lung cancer
prospectively underwent PET-CT and DWI before pulmonary re-
section. Of these patients, 88 patients with NSCLC who underwent
pulmonary resection and mediastinal lymph node dissection were
enrolled in this study. The histologic types of lung cancer were
adenocarcinoma in 67 patients, squamous cell carcinoma in 18
patients, and adenosquamous carcinoma in 3 patients (Table 1).
The pathologic N stages were N0 in 71 patients, N1 in 9 patients,
and N2 in 8 patients. The lymph node stations were classified ac-
cording to the lymph node map of Naruke, which is approved by
the Japan Lung Cancer Society.19
PET-CT Scanning
Patients were instructed to fast for at least 5 hours before intravenous
administration of FDG. The administered dosage of FDG was 100
mCi/kg (3.7 MBq/kg) of body weight. PET imaging was performed
approximately 60 minutes after intravenous administration of the
FDG by using an integrated PET-CT device (Discovery ST; GE
Medical Systems) that consisted of a PET scanner (Advance Nx;
GE Medical Systems) and an 8-section CT scanner (Light Speed
Plus; GE Medical Systems).
The acquisition time for PET in 3-dimensional mode was 3 min-
utes per table position. CT data were resized from a 5123 512 ma-
trix to a 128 3 128 matrix to match the PET data to allow image
fusion, and a CT transmission map was generated. PET imageracic and Cardiovascular Surgery c Volume 135, Number 4 817
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expectation maximization algorithm with segmented attenuation
correction (4 iterations, 28 subsets) and the CT data. The 3.75-
mm-thick transaxial CT images were reconstructed at 3.27-mm
intervals (transaxial) for fusion with the transaxial PET images.
The PET, CT, and fused images were available for review in axial,
coronal, and sagittal planes by using software (Xeleris; GE Medical
Systems) on a computer workstation.
DWI
All magnetic resonance images were obtained with a 1.5-T super-
conducting system (Gyroscan Intera Achieva Nova Dual; Philips
Medical Systems). Conventional magnetic resonance images and
DWI were acquired during the same procedure. The conventional
magnetic resonance images consisted of a coronal T1-weighted se-
quence (repetition time [TR] in milliseconds/echocardiographic
time [TE] in milliseconds/excitations: 234/4/1), a coronal and axial
single-shot spin echocardiographic T2-weighted (800/90/1) se-
quence, and a coronal and axial short tau inversion recovery
(STIR; TR/TE/inversion time, 4600/90/160) sequence. The T1-
weighted, T2-weighted, and STIR sequences were acquired at a
section thickness of 6 mm with a 1-mm intersection gap, a 128 3
128 – 256 matrix, and a 40- to 45-cm field of view.
DWI was performed for the thorax in the transverse plane by us-
ing a spin echocardiographic, echoplanar imaging sequence with the
following parameters: TR/TE/flip angle, 5900/60/90; diffusion gra-
dient encoding in 3 orthogonal directions; b value, 1000 s/mm2; field
of view, 400 mm; matrix size, 1123 100; section thickness, 6 mm;
section gap, 1 mm; and number of signals acquired, 6. DWI data
were evaluated semiquantitatively by using the ADC. The ADC
was calculated as follows: ADC52½InðS=S0Þ=b, where S is the sig-
nal intensity of the region of interest obtained through 3 orthogo-
nally oriented DWIs and b is the gradient b factor with a value of
1000 s/m2.
TABLE 1. Patient characteristics
Mean age, y (range) 70 6 9 (38–82)
Male sex 47
Female sex 41
Mean tumor size, cm (range) 2.1 6 1.0 (0.5–8.0)
Tumor location
Right upper lobe 29
Right middle lobe 5
Right lower lobe 25
Left upper lobe 20
Left lower lobe 9
Histologic type
Adenocarcinoma 62
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Two radiologists (KK and SS, with 14 and 11 years, respectively, of
radioisotope scintigraphy and PET interpretation experience) evalu-
ated the PET-CT data before the operation. N staging by means of
PET-CT was determined as follows. The region of interest was
placed on the lymph nodes more than 1 cm in the long axis, for
which the standard uptake value (SUV) was measured. The contrast
ratio (CR) of SUV (SUV-CR) was calculated as the SUV of the
lymph nodes divided by the SUV of the cerebellum in each lymph
node, as reported previously.1
N Staging by means of DWI
One radiologist (KK, with 14 years of MRI interpretation experi-
ence) evaluated the MRI data before the operation. N staging by
means of DWI was determined as follows: the region of interest
was placed on the lymph nodes more than 1 cm in the long axis,
and the minimum ADC value (ADC-min) was measured.
Determining the Cutoff Values of SUV-CR
and ADC-min
A receiver operating characteristic curve was constructed from the
SUV-CR and ADC-min data by using SPSS software (SPSS 15.0
J for Windows, SPSS, Inc), and the cutoff values for a diagnosis
of metastasis were determined. Lymph nodes with SUV-CR values
of greater than the cutoff value were defined as positive by means of
PET-CT. Lymph nodes with SUV-CR values of less than the cutoff
value or those that could not be detected on PET-CT were defined as
negative by means of PET-CT. By using DWI, lymph nodes with
ADC-min values of less than the cutoff value were defined as pos-
itive by means of DWI. Lymph nodes with ADC-min values of
greater than the cutoff value or those that could not be detected on
DWI were defined as negative by means of DWI.
Measuring the Size of Metastatic Foci
The long-axis diameters of metastatic foci within lymph nodes were
measured on hematoxylin and eosin–stained sections with a micro-
scope to compare the detectable size of metastatic foci between
PET-CT and DWI.
Statistical Analysis
True-positive (TP), true-negative (TN), false-positive (FP), and
false-negative (FN) results of PET-CT and DWI images for the di-
agnosis of lymph node metastasis were compared with the results of
the pathologic diagnosis. Sensitivity was calculated as TP=TP1FN,
specificity as TN=TN1FP, and accuracy as TP1TN=Total. The
sensitivity, specificity, and accuracy of PET-CT versus DWI for
N staging and diagnosing each lymph node station were compared
by using a McNemar test. The size of the metastatic foci was ana-
lyzed by using the 2-tailed Student t test. All values in the text
and tables are given as means 6 standard deviation.
Results
DWI identified metastatic lymph nodes, as well as primary
tumors, like PET images (Figure 1). Eighty lymph nodes in
the 88 patients that were greater than 1 cm in their longest
axis were studied to determine the cutoff values with the re-
ceiver operating characteristic curves. The receiver operatingril 2008
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80 lymph nodes showed an optimal cutoff value of SUV-
CR on PET-CT to be 0.26 and ADC-min on DWI to be
1.6 3 1023 mm2/s (Figures 2 and 3).
Table 2 shows the results of N staging with PET-CT and
DWI. Among the 88 patients, PET-CT correctly identified
the pathologic N stage in 69 patients, with overstaging in
12 patients and understaging in 7 patients, giving a staging
accuracy of 0.78. DWI images correctly identified the patho-
logic N stage in 78 patients, with overstaging in 4 patients
and understaging in 6 patients, giving a staging accuracy of
0.89.
Tables 3 to 6 show the data for the analysis by using the
McNemar test. Both PET-CT and DWI gave correct N stag-
ing in 68 patients but incorrect staging in 9 patients (Table 3).
Although N staging was correct by means of PET-CT but in-
correct by means of DWI in 1 patient, it was correct by means
of DWI but incorrect by means of PET-CT in 10 patients.
DWI diagnosed N staging significantly more accurately
than PET-CT because of a reduction in overstaging (McNe-
mar test, P 5 .02).
Of the 734 lymph node stations examined, 36 had metas-
tases, and the other 698 did not. In the 36 metastatic lymph
node stations, both PET-CT and DWI produced TP results
in 24 and FN results in 10 (Table 4). Although results for 2
metastatic lymph node stations were TP with PET-CT but
Figure 1. Diffusion-weighted magnetic resonance imaging with
a reversed gray scale in adenocarcinoma of the right lower lobe
with hilar lymph node metastases, which shows similar images
of positron emission tomography.The Journal of ThoraFN with DWI, results of none of the metastatic lymph nodes
were TP with DWI but FN with PET-CT. The sensitivities of
PET-CT and DWI were 0.72 (95% confidence interval,
0.65–0.87) and 0.67 (95% confidence interval, 0.52–0.82),
respectively. There was no significant difference in the diag-
nosis of metastatic lymph node stations between PET-CT
and DWI (McNemar test, P 5 .5).
In the 698 nonmetastatic lymph node stations, results of
both PET-CT and DWI were FP in 3 and TN in 678 (Table 5).
Although results with 15 nonmetastatic lymph node stations
were FP with PET-CT but TN with DWI, 2 were FP with
DWI but TN with PET-CT. The specificities of PET-CT
and DWI were 0.97 (95% confidence interval, 0.962–
0.986) and 0.99 (95% confidence interval, 0.987–0.996),
respectively. DWI showed a greater specificity than PET-
CT (McNemar test, P 5 .002). The 18 lymph node stations
that had FP results on PET-CT showed histologic findings of
nonspecific lymphadenitis (n 5 15) or tuberculosis (n 5 3),
with a mean size on CT of 12 6 2 mm (range, 10–14 mm).
The 5 lymph node stations that had FP results on DWI
showed tuberculosis (n 5 3) or nontuberculosis (n 5 2)
granulation, with a mean size on CT of 12 6 2 mm (range,
10–14 mm). The results of DWI were not FP for the 15 sta-
tions with nonspecific lymphadenitis, which were FP with
PET-CT.
In the overall 734 lymph node stations, both PET-CT and















Figure 2. Receiver operating characteristic curve and standard
uptake value–contrast ratio value for diagnosing lymph node me-
tastasis on positron emission tomography–computed tomography
shows the optimal cutoff value to be 0.26. Area under the curve,
0.79; 95% confidence interval, 0.69 to 0.89.cic and Cardiovascular Surgery c Volume 135, Number 4 819
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was correct by means of PET-CT but incorrect by means
of DWI in 4 lymph node stations, it was correct by means
of DWI but incorrect by means of PET-CT in 15 stations.
DWI diagnosed lymph node stations significantly more accu-
rately than PET-CT because of fewer FP results (McNemar
test, P 5 .019).
The sizes of the metastatic foci in the lymph nodes that had
FN results on PET-CT ranged from 0.5 to 3 mm, with a mean
value of 1.26 0.9 mm, whereas those with TP results ranged
from 3 to 13 mm, with a mean value of 96 4 mm (Figure 4).
There was a significant difference in the size of metastatic
foci between the FN and TP lymph nodes (P , .001). PET
was unable to detect any of the metastatic foci smaller than
4 mm, except for one foci with 3 mm, but detected all those
larger than 4 mm.
TABLE 2. N staging by means of positron emission
tomography and diffusion-weighted magnetic resonance
imaging
Incorrect, n (%)
Correct, n (%) Overstaging, n (%) Understaging, n (%) Total
PET-CT 69 (78) 12 (14) 7 (8) 88
DWI 78 (89) 4 (5) 6 (7) 88
PET-CT, Positron emission tomography–computed tomography; DWI, diffu-















Figure 3. Receiver operating characteristic curve and apparent
diffusion coefficient value for diagnosing lymph node metastasis
on diffusion-weighted magnetic resonance imaging shows the op-
timal cutoff value to be 1.6 3 1023 mm2/s. Area under the curve,
0.82; 95% confidence interval, 0.71 to 0.94.820 The Journal of Thoracic and Cardiovascular Surgery c AprThe sizes of the metastatic foci that had FN results on
DWI ranged from 0.5 to 8 mm, with a mean value of 2.0
6 2.3 mm, whereas those with TP results ranged from 3 to
13 mm, with a mean of 10 6 4 mm (Figure 5). There was
a significant difference in the size of metastatic foci between
the lymph nodes with FN and TP results (P , .001). DWI
was unable to detect any of the metastatic foci smaller than
4 mm, except for one focus with 3 mm, but detected all those
larger than 4 mm except for one focus of adenocarcinoma 8
mm in size.
Discussion
This study showed a superiority of DWI to PET-CT for N
staging in patients with NSCLC because of fewer FP diagno-
ses in the former. FP diagnosis with PET-CT caused by con-
current lymphadenitis is well known for N staging in patients
with NSCLC.1,8 Most of the lymph nodes with FP results on
PET-CT in this study also showed histologic findings of
lymphadenitis, whereas DWI did not show FP results for
them. We therefore conclude that DWI can be used in place
of PET-CT for N staging of NSCLC and that it is also asso-
ciated with a reduction in the number of overstagings com-
pared with PET-CT.
The difference in the ADC value between metastatic and
nonmetastatic lymph nodes is considered to be caused by
the difference in cellularity and structural features between
TABLE 3. Correlation of accuracy for N staging between





Correct 68 10 78
Incorrect 1 9 10
Total 69 19 88
PET-CT, Positron emission tomography–computed tomography; DWI, diffu-
sion-weighted magnetic resonance imaging. McNemar test: p 5 .012.
TABLE 4. Correlation between positron emission
tomography and diffusion-weighted magnetic resonance





True-positive 24 0 24
False-negative 2 10 12
Total 26 10 36
PET-CT, Positron emission tomography–computed tomography; DWI, diffu-
sion-weighted magnetic resonance imaging. Sensitivity of PET-CT, 0.72
(95% confidence interval, 0.65–0.87); sensitivity of DWI, 0.67 (95% confi-
dence interval, 0.52–0.82). McNemar test: P 5 .5.il 2008
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larger nuclei with more abundant macromolecular proteins,
nuclear cytoplasmic ratios, and less extracellular space than
benign nodes, which reduce diffusion of water molecules
on DWI, resulting in decreased ADC values.12,13 The signif-
icant decrease in FP results on DWI might be due to the fol-
lowing reasons: although the nonspecific lymphadenitis
increases FDG uptake, this would not change the basic archi-
tecture of lymph nodes, resulting in a similar ADC value be-
tween lymphadenitis and normal lymph nodes. However,
granulation tissue in tuberculosis or nontuberculosis lymph
nodes showed FP results on DWI because an architectural
change with granulation tissue decreases the diffusion of
water molecules on DWI.
Although SUV has frequently been used for evaluation of
FDG-PET, it has been reported that several factors can affect
the SUV, such as body size,20 blood glucose level,21 and time
after injection.22 We previously compared the results of
SUV-max, SUV-CR with contralateral lung, and SUV-CR
with cerebellum for pulmonary nodules and reported that
SUV-CR with contralateral lung or cerebellum showed
significantly higher sensitivity than SUV-max,23 a result sup-
ported by Obrzut and associates.24
TABLE 5. Correlation between positron emission
tomography and diffusion-weighted magnetic resonance





False-positive 3 2 5
True-negative 15 678 693
Total 18 680 698
PET-CT, Positron emission tomography–computed tomography; DWI, diffu-
sion-weighted magnetic resonance imaging. Specificity of PET-CT, 0.97
(95% confidence interval, 0.962–0.986); specificity of DWI, 0.99 (95% confi-
dence interval, 0.987–0.996). McNemar test: P 5 .002.
TABLE 6. Correlation of accuracy for diagnosis of over all
lymph node stations between positron emission





Correct 702 15 717
Incorrect 4 13 17
Total 706 28 734
PET-CT, Positron emission tomography–computed tomography; DWI,
diffusion-weighted magnetic resonance imaging. Correct: true-positive 1
true-negative results; incorrect: false-positive 1 false-negative results.
McNemar test: P 5 .019.The Journal of ThoAlthough the present study showed the cutoff value of
ADC-min for diagnosing metastatic lymph nodes to be 1.6
3 1023 mm2/s, our recent study for diagnosing malignant
pulmonary nodules by means of DWI showed the cutoff
value of ADC-min to be 1.1 3 1023 mm2/s. The reason
why the cutoff value of ADC for diagnosing metastatic
lymph nodes was higher than that for diagnosing malignant
pulmonary nodules could be due to the fact that the ADC
value of lymph nodes might increase with motion artifact


















Figure 4. The distribution of sizes of metastatic foci in false-
negative and true-positive lymph nodes with positron emission
tomography–computed tomography (PET-CT). The difference



















Figure 5. The distribution of sizes of metastatic foci in false-
negative and true-positive lymph nodes with diffusion-weighted
imaging (DWI). The difference between them was a P value of
less than .001.racic and Cardiovascular Surgery c Volume 135, Number 4 821
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nary nodules should be little affected by these motion arti-
facts. The cutoff value of SUV-CR on PET-CT for
differentiating metastatic lymph nodes was 0.26 in this study,
which was similar to our previous report and others.1,24
FN results were similar between PET-CT and DWI. Both
diagnostic tools had very limited ability to detect lymph no-
des with metastatic foci smaller than 4 mm. Considering the
spatial resolution of the PET scanner, artifacts resulting from
respiratory movements, and image reconstruction, it is diffi-
cult to evaluate such small metastatic foci. Even on DWI,
STIR sequences were acquired at a section thickness of 6
mm, causing lymph nodes with small metastatic foci to be
missed.We previously reported that 32% ofmetastatic lymph
nodes of NSCLC had metastatic foci smaller than 4 mm.1 Be-
cause neither PET-CT nor DWI was able to detect metastatic
foci smaller than 4 mm, which were not unusual sizes of met-
astatic lymph nodes in NSCLC, lymph node dissection can-
not be reduced for patients with N0 stage NSCLC diagnosed
by means of either PET-CT or DWI.
Our study had the following limitations: (1) because the
patients in the present study were referred to surgical inter-
vention, 71 (81%) of 88 patients had N0 disease, which might
cause a group-specific bias and a superiority of DWI to PET,
and (2) DWI in the present study just examined the thorax
and not the whole body, whereas PET-CT showed the whole
body. Recently, whole-body DWI has become available.
Lichy and colleagues25 compared the tumor detection be-
tween whole-body DWI and PET-CT for 19 patients with
various kinds of tumors, showing a feasibility of the former
for clinical practice. We believe that whole-body DWI will
be used routinely for TNM staging of patients with lung
cancer in the near future.
MRI has the following advantages over PET: (1) patients
do not have to fast before examination; (2) there is no radia-
tion exposure; (3) less time is required for examination (30
minutes for DWI vs 90 minutes for PET-CT); and (4) there
is less cost ($100 for DWI vs $700 for PET-CT in Japan). Al-
though PET-CT is still superior to DWI on whole-body im-
aging, this study showed that that DWI can be used in
place of PET-CT for N staging of NSCLC and is associated
with significantly fewer FP results compared with PET-CT.
In the future, a multicenter study with a larger dataset will
be necessary.
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